Page last updated: 2024-09-05

lasofoxifene and Carcinoma, Ductal, Breast

lasofoxifene has been researched along with Carcinoma, Ductal, Breast in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Allred, DC; Armstrong, R; Cummings, SR; Curto, M; Eastell, R; Ensrud, KE; Goss, P; LaCroix, AZ; Lee, A; Neven, P; Osborne, CK; Powles, T; Reid, DM; Thompson, DD; Thompson, JR; Vukicevic, S; Wolter, K	1

Trials

1 trial(s) available for lasofoxifene and Carcinoma, Ductal, Breast

Article	Year
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. Journal of the National Cancer Institute, 2010, Nov-17, Volume: 102, Issue:22 Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Biomarkers, Tumor; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Double-Blind Method; Estradiol; Female; Fractures, Bone; Humans; Incidence; Mammography; Middle Aged; Odds Ratio; Osteoporosis, Postmenopausal; Primary Prevention; Pyrrolidines; Receptors, Estrogen; Risk Assessment; Selective Estrogen Receptor Modulators; Sex Hormone-Binding Globulin; Tetrahydronaphthalenes; Treatment Outcome; United States	2010

Article

Year

Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.

Journal of the National Cancer Institute, 2010, Nov-17, Volume: 102, Issue:22

Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Biomarkers, Tumor; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Double-Blind Method; Estradiol; Female; Fractures, Bone; Humans; Incidence; Mammography; Middle Aged; Odds Ratio; Osteoporosis, Postmenopausal; Primary Prevention; Pyrrolidines; Receptors, Estrogen; Risk Assessment; Selective Estrogen Receptor Modulators; Sex Hormone-Binding Globulin; Tetrahydronaphthalenes; Treatment Outcome; United States

2010